Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcus Biosciences (RCUS) Asset Writedowns and Impairment (2024)

Arcus Biosciences (RCUS) has 2 years of Asset Writedowns and Impairment data on record, last reported at -$20.0 million in Q4 2025.

  • For Q4 2025, Asset Writedowns and Impairment changed N/A year-over-year to -$20.0 million; the TTM value through Dec 2025 reached -$20.0 million, changed N/A, while the annual FY2024 figure was $20.0 million, N/A changed from the prior year.
  • Asset Writedowns and Impairment reached -$20.0 million in Q4 2025 per RCUS's latest filing, down from $20.0 million in the prior quarter.
  • Across five years, Asset Writedowns and Impairment topped out at $20.0 million in Q1 2024 and bottomed at -$20.0 million in Q4 2025.